OC
CYTK icon

Oppenheimer & Co’s Cytokinetics CYTK Stock Holding History

Oppenheimer & Co’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Buy
3,929
+21
+0.5% +$1.51K ﹤0.01% 1432
2026
Q1 		$258K Sell
3,908
-14
-0.4% -$890 ﹤0.01% 1455
2025
Q4 		$249K Sell
3,922
-450
-10% -$28K ﹤0.01% 1346
2025
Q3 		$240K Sell
4,372
-2,490
-36% -$103K ﹤0.01% 1476
2025
Q2 		$227K Sell
6,862
-1,532
-18% -$53.3K ﹤0.01% 1457
2025
Q1 		$337K Sell
8,394
-79
-0.9% -$3.63K 0.01% 1219
2024
Q4 		$399K Sell
8,473
-73
-0.9% -$3.79K 0.01% 1155
2024
Q3 		$451K Buy
8,546
+824
+11% +$45.9K 0.01% 1076
2024
Q2 		$418K Sell
7,722
-606
-7% -$36.6K 0.01% 1064
2024
Q1 		$584K Buy
8,328
+5,158
+163% +$399K 0.01% 942
2023
Q4 		$265K Buy
+3,170
New +$115K ﹤0.01% 1191

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer & Co's CYTK Position: Q2 2026 in Review

Oppenheimer & Co increased its Cytokinetics (CYTK) stake by 0.54% in Q2 2026, buying an estimated $1.51K and bringing the position to 3,929 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #1432.

Oppenheimer & Co first reported a position in CYTK in Q4 2023 and has held it in 11 quarters since. The position peaked at $584K in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Oppenheimer & Co held 3,929 shares of Cytokinetics worth $335K as of Q2 2026.
  • Oppenheimer & Co bought 21 Cytokinetics shares in Q2 2026, an estimated $1.51K.
  • Cytokinetics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1432 holding.
  • Oppenheimer & Co first reported a position in Cytokinetics in Q4 2023 and has held it in 11 quarters since.
  • Oppenheimer & Co's Cytokinetics position peaked at $584K in Q1 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.